Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter net profit. In an interview with CNBC-TV18, Surajit Pal, pharma analyst, Elara Capital said, the top-line is very much in line, just 3% below his expectations. “Bottom-line margin has increased quite significantly, much above our expectation,” he added.
first published: Jul 26, 2011 03:24 pm
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
